机构:[1]Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China临床科室高血压科首都医科大学附属安贞医院[2]Department of Otolaryngology Head and Neck Surgery, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China临床科室耳鼻咽喉头颈外科首都医科大学附属安贞医院[3]Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, Blood Vessel Diseases, 100029 Beijing, China临床科室高血压科首都医科大学附属安贞医院
Hypertension, a multifactorial disease, is a major risk factor for the development of stroke, coronary artery disease, heart failure, and chronic renal failure. However, its underlying cellular and molecular mechanisms remain largely elusive. Numerous studies have shown that microRNAs (miRNAs) are involved in a variety of cellular processes, including cellular proliferation, apoptosis, differentiation, and the development of diseases. microRNA-21 (miR-21), a conserved single-stranded non-coding RNA that is composed of approximately 22 nucleotides, is one of the most intensively studied miRNAs in recent years, and it can regulate gene expression at the post-transcriptional level. miR-21 is expressed in many kinds of tumors and in the cardiovascular system, and it plays an important role in the occurrence and development of cardiovascular diseases. In recent years, more and more evidence indicates that miR-21 plays an important role in hypertension. This article reviews the source, function, and altered levels of miR-21 in hypertension and the role of miR-21 in the pathogenesis of hypertension and target organ damage (TOD). The potential role of miR-21 as a new target for predicting and treating hypertension is also explored.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81370229, 81270216]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7102045]; Personnel Training Plan of High-Level Health Technical Talent in the Beijing Health System [2014-3-040]; International Science and Technology Cooperation Program of China [2015DFA30160]
第一作者机构:[1]Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
通讯作者:
通讯机构:[2]Department of Otolaryngology Head and Neck Surgery, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China[3]Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, Blood Vessel Diseases, 100029 Beijing, China
推荐引用方式(GB/T 7714):
Li Xiao,Wei Yongxiang,Wang Zuoguang.microRNA-21 and hypertension[J].HYPERTENSION RESEARCH.2018,41(9):649-661.doi:10.1038/s41440-018-0071-z.
APA:
Li, Xiao,Wei, Yongxiang&Wang, Zuoguang.(2018).microRNA-21 and hypertension.HYPERTENSION RESEARCH,41,(9)
MLA:
Li, Xiao,et al."microRNA-21 and hypertension".HYPERTENSION RESEARCH 41..9(2018):649-661